By Robb M. Stewart
Bausch + Lomb swung to a loss in the latest quarter as a rise in the Canadian eye-health company's income tax provision offset a rise in revenue across its business segments.
The company recorded a net loss of $28 million, or 8 cents a share, against a year-earlier profit of $4 million, or 1 cent.
Third-quarter earnings before interest, taxes, depreciation and amortization on an adjusted basis expanded to $243 million from $212 million.
Revenue for the quarter was up 7.1% at $1.28 billion, in line with the median forecast of analysts polled by FactSet. Excluding a $19 million boost from favorable foreign exchange rates, it said its revenue increased about 6% on last year.
Bausch + Lomb, whose products include contact lenses, pharmaceuticals and ophthalmic surgical devices, said vision care revenue was up 7.6% to $736 million, while surgical revenue rose 4.4% to $215 million and pharma revenue increased 7.8% to $330 million.
The company narrowed its earnings target for the full year, forecasting adjusted Ebitda of between $870 million and $910 million. That comes after Bausch + Lomb in July raised the guidance to between $860 million and $910 million.
It affirmed guidance for annual revenue of $5.05 billion to $5.15 billion, but said it now anticipates a foreign exchange tailwind of $30 million for the year, where it previously forecast a $25 million benefit in 2025.
The Wall Street Journal earlier this month reported that activist investor Jana Partners has built a stake in Cooper Cos. and plans to push for strategic alternatives, including a potential deal to combine its contact-lens unit with Bausch + Lomb. People familiar with the matter said Jana thinks a investors would be attracted to a tie-up of Cooper's and Bausch + Lomb's contact-lens businesses, both compete with Johnson & Johnson and Switzerland-based Alcon.
Bausch + Lomb is majority owned by pharmaceutical company Bausch Health, which has long sought to spin off its subsidiary and earlier this year said it continued to work on possible alternatives after failing to clinch a deal with a private-equity suitor interested in the eye-health company.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
October 29, 2025 07:25 ET (11:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Comments